Amorphous Solid Dispersions for HIF-2α Inhibitor Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for HIF-2α-mediated diseases, such as renal cell carcinoma and von Hippel-Lindau disease, face challenges in achieving effective delivery and stability of HIF-2α inhibitors due to their crystalline nature, which affects bioavailability and solubility.
Innovation Solution
Development of amorphous solid dispersions comprising a HIF-2α inhibitor, such as 3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile, dispersed in a polymer matrix like HPMCAS, to enhance stability and solubility, allowing for effective oral delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If HIF-2α inhibitors are formulated in crystalline form, then manufacturing stability is improved, but bioavailability and solubility deteriorate
Solution Approach 1:
The patent transforms the physical state of the HIF-2α inhibitor from crystalline to amorphous form, fundamentally changing its physical parameters. This parameter change enables the compound to achieve both improved solubility and bioavailability while maintaining manufacturing stability through controlled amorphous solid dispersion formulation
Solution Approach 2:
The patent creates a composite material system consisting of amorphous HIF-2α inhibitor dispersed within a polymer matrix (such as HPMCAS). This composite structure combines the therapeutic agent with excipients to achieve enhanced solubility, bioavailability, and manufacturing stability simultaneously
2Stability of the object's composition
If HIF-2α inhibitors are formulated in crystalline form, then structural stability is improved, but solubility deteriorates
Solution Approach 1:
The patent changes the physical state parameter from crystalline to amorphous, eliminating the rigid crystal lattice structure that limits solubility. The amorphous form lacks long-range molecular order, allowing better interaction with solvents and improved dissolution characteristics while maintaining formulation stability
Solution Approach 2:
The patent introduces polymer excipients (such as HPMCAS, PVP, or SOLUPLUS) as intermediary materials that stabilize the amorphous state of the HIF-2α inhibitor. These polymers act as matrices that prevent recrystallization and maintain the high-energy amorphous state, thereby improving solubility while preserving structural stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The amorphous solid dispersions improve bioavailability and solubility of HIF-2α inhibitors, enhancing therapeutic efficacy in treating HIF-2α-mediated diseases by maintaining stability and facilitating controlled release.
Implementation Method 1
Development of amorphous solid dispersions comprising a HIF-2α inhibitor, such as 3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile, dispersed in a polymer matrix like HPMCAS, to enhance stability and solubility
Data Source
AI summary
Provided herein are solid dispersions comprising a HIF-2α inhibitor, pharmaceutical compositions comprising the solid dispersions, and methods for treating HIF-2α-mediated diseases and conditions.